Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROACT: Enalapril for Cardiotoxicity Prevention
NCT03265574Phase 3Completed
- Sponsor
- South Tees Hospitals NHS Foundation Trust
- Start
- Oct 2017
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enalapril in anthracycline-induced cardiotoxicity (2 arms), sponsored by South Tees Hospitals NHS Foundation Trust. Primary endpoint: Cardiac troponin T release. Started Oct 2017; status: completed.
02
Drugs
enalapril
03
Conditions
anthracycline-induced cardiotoxicity
Beyond the preview
Go deeper on NCT03265574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03265574.